Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 16/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.42 |
| ▸ | CDK2 | P24941 | 4/20 | 0.42 |
| ▸ | CDK9 | P50750 | 4/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1913448 | 1.00 | PDPK1 (0.50) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1913619 | 1.00 | PDPK1 (0.50) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1913606 | 0.89 | PDPK1 (0.49) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1913605 | 0.89 | PDPK1 (0.49) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1913609 | 0.87 | PDPK1 (0.53) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1913542 | 0.81 | PDPK1 (0.53) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1913414 | 0.81 | PDPK1 (0.61) | PDPK1 | |
| SCHEMBL12530664 | 0.79 | PDPK1 (0.41) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL15355421 | 0.78 | PDPK1 (0.48) | PDPK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1913548 | 0.77 | PDPK1 (0.41) | PDPK1CCNT1CCNA2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516431-B1 | PYRROLOPYRIDINYL-PYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-8575163-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-11-05 | — | — | US | claimed |
| US-20120270871-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-25 | — | — | US | claimed |
| EP-2516431-B1 | PYRROLOPYRIDINYL-PYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
| EP-2516431-B1 | PYRROLOPYRIDINYL-PYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
| US-8575163-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8575163-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8575163-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| EP-2516431-A1 | PYRROLOPYRIDINYL-PYRIMIDIN-2-YLAMINE DERIVATIVES | Merck Patent GmbH (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20120270871-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270871-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270871-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-25 | — | — | US | disclosed |
| WO-2011076316-A1 | PYRROLOPYRIDINYL-PYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270871-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | MKI67, CCNI, CCNT1 | PDPK1 425/4885CCNT1 3/4885CCNA2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.